Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | OGG1 | O15527 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cg-200745 SCHEMBL29352975 | 1.00 | HTR1B (0.44) | HTR1BMAPTKDM4EALDH1A1HPGD | |
| Cg-200745 SCHEMBL29761004 | 1.00 | HTR1B (0.44) | HTR1BMAPTKDM4EALDH1A1HPGD | |
| Cg-200745 SCHEMBL16166645 | 1.00 | HTR1B (0.44) | HTR1BMAPTKDM4EALDH1A1HPGD | |
| Cg-200745 SCHEMBL29761007 | 0.99 | HTR1B (0.43) | HTR1BMAPTKDM4EALDH1A1HPGD | |
| Cg-200745 SCHEMBL23071642 | 0.97 | HTR1B (0.41) | HTR1BMAPTKDM4EALDH1A1HPGD | |
| Cg-200745 SCHEMBL29412219 | 0.97 | HTR1B (0.41) | HTR1BMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL22403025 | 0.90 | HTR1B (0.45) | HTR1BMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL25500010 | 0.89 | HTR1B (0.43) | HTR1BMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL23071643 | 0.88 | OGG1 (0.41) | HTR1BMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL1306605 | 0.88 | KDM4E (0.39) | HTR1BMAPTKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777847-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FIBROSIS | Crystalgenomics, Inc. (KR) | 2021-02-17 | — | — | EP | claimed |
| US-20210015772-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FIBROSIS | CRYSTALGENOMICS, INC. (KR) | 2021-01-21 | — | — | US | claimed |
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | claimed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | claimed |
| US-12553903-B2 | Ivaltinostat combination therapy for treating pancreatic cancer | CG PHARMACEUTICALS, INC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250152526-A1 | USES OF IVALTINOSTAT FOR TREATING PANCREATIC CANCER | CG PHARMACEUTICALS, INC | 2025-05-15 | — | — | US | disclosed |
| US-20240402191-A1 | IVALTINOSTAT COMBINATION THERAPY FOR TREATING PANCREATIC CANCER | CG PHARMACEUTICALS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20220287993-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | CRYSTALGENOMICS, INC. (KR) | 2022-09-15 | — | — | US | disclosed |
| WO-2022177054-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION | 크리스탈지노믹스(주) | 2022-08-25 | — | — | WO | disclosed |
| EP-4026544-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | Crystalgenomics, Inc. (KR) | 2022-07-13 | — | — | EP | disclosed |
| WO-2021045392-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | 크리스탈지노믹스(주) | 2021-03-11 | — | — | WO | disclosed |
| EP-3777847-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FIBROSIS | Crystalgenomics, Inc. (KR) | 2021-02-17 | — | — | EP | disclosed |
| US-20210015772-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FIBROSIS | CRYSTALGENOMICS, INC. (KR) | 2021-01-21 | — | — | US | disclosed |
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160069887-A1 | BIOMARKERS FOR PROGNOSIS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2016-03-10 | — | — | US | disclosed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | disclosed |
| WO-2014167311-A1 | BIOMARKERS FOR PROGNOSIS | ISIS INNOVATION LIMITED (GB) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220287993-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | PDCD1, HDAC1, HDAC5 | HTR1B 3755/4885MAPT 865/4885KDM4E 324/4885 |
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | HTR1B 429/4885MAPT 953/4885KDM4E 2446/4885 |
| US-20250152526-A1 | USES OF IVALTINOSTAT FOR TREATING PANCREATIC CANCER | RNASE1, G6PC1, GLP1R | HTR1B 3846/4885MAPT 3638/4885KDM4E 1306/4885 |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | HTR1B 429/4885MAPT 953/4885KDM4E 2446/4885 |
| US-20210015772-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FIBROSIS | FIBP, MMP1, CFTR | HTR1B 2232/4885MAPT 4436/4885KDM4E 1709/4885 |
| US-20240402191-A1 | IVALTINOSTAT COMBINATION THERAPY FOR TREATING PANCREATIC CANCER | RNASE1, SERPINB1, IGFBP1 | HTR1B 3714/4885MAPT 3844/4885KDM4E 1858/4885 |
| US-12553903-B2 | Ivaltinostat combination therapy for treating pancreatic cancer | VCAM1, SELPLG, EPCAM | HTR1B 4217/4885MAPT 1364/4885KDM4E 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.